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ABSTRACT
Background: Renal denervation (RDN) is a new treatment for hypertension in patients with chronic
kidney disease (CKD), but its efficacy is still debated. This meta-analysis aimed to evaluate the efficacy
and safety of RDN for hypertension in patients with CKD.
Methods: PubMed, Web of Science, EMBASE, and Ovid databases were searched for relevant studies
published. We performed both fixed- and random-effects meta-analyses of the changes in blood pres-
sure, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR)
after RDN.
Results: The meta-analysis included 238 patients from 11 single-center, non-randomized, uncontrolled
studies. Office blood pressure and 24-hour ambulatory blood pressure (24 h-ABP) showed a significant
reduction 1month after RDN (p< 0.05). This decrease of 24 h-ABP persisted for 24months after RDN
showed difference systolic blood pressure (p< 0.001) and diastolic blood pressure (p¼ 0.001). The
24h-ABP exhibited a similar trend in the subgroup analysis. eGFR measurements obtained at each
time point of analysis after RDN were not significantly different from those obtained before (p> 0.05).
UACR levels were significantly reduced at 3months and 6months after RDN (p< 0.001). After RDN, the
heart rate showed no significant changes (p> 0.05), and few major complications were encountered.
Conclusions: The meta-analysis showed that RDN may be effective and safe for treating CKD patients
with hypertension. Well-designed randomized controlled trials of RDN are urgently needed to confirm
the safety and reproducibility of RDN and to assess its impact on clinical outcomes.
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Chronic kidney disease (CKD) is a progressive chronic disease
that carries a high burden of morbidity and mortality and
affects more than 10% of the world’s population [1,2]. CKD
often coexists with several chronic conditions, including dia-
betes, hypertension, and heart failure [3]. Hypertension is
also a major factor that causes both CKD mortality and car-
diovascular diseases [4].
In patients with CKD, hypertension establishment and
maintenance are often critically dependent on numerous fac-
tors, including volume overload, activation of the renin-
angiotensin system, increased endothelin levels, reduced
nitric oxide bioavailability and/or medullary vasodilating fac-
tors, and oxidative stress [5]. For a long time, volume over-
load and renin-angiotensin axis activation have been
acknowledged as the most actively involved parameters in
the pathogenesis of renal hypertension. However, in clinical
practice, treatments for these aspects are not always accom-
panied by the expected reduction in blood pressure (BP).
After years of research, sustained activation of the sympa-
thetic nervous system (SNS) in CKD has been demonstrated
to play a crucial role in the pathogenesis and maintenance
of hypertension and the progression of CKD [6].
In CKD, stimulation of the renal afferent nerves is caused
by factors such as ischemia, and uremic toxins increase sys-
temic sympathetic outflow. Sustained overactivity of SNS
increases BP and aggravates further deterioration of the renal
function at the same time [7]. Under such circumstances,
even with several antihypertensive drugs, drug therapy is
usually ineffective in patients with CKD [8].
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The kidney is an effector organ for sympathetic nerve out-
flow and an important regulator of SNS activity; thus, block-
ing overactivity of the renal sympathetic nerve in CKD may
be a reasonable treatment option for lowering BP and delay-
ing the deterioration of kidney function [9].
Renal denervation (RDN), also called catheter-based renal
denervation, has been developed in recent years [10].
Compared with surgical denervation, most commonly
splanchnicectomy, this more minimally invasive and efficient
radiofrequency-induced RDN has been shown to benefit
patients with resistant hypertension [11], and convincing
results of many experimental hypertension with CKD animal
model studies have shown that it effectively reduce BP and
protect the kidneys [9]. RDN appears to be a sensible treat-
ment approach for CKD patients with hypertension. Some
subgroup analyses from larger clinical trials and smaller
research on mechanisms have started to explore this further.
Although a comprehensive review on this topic has been
published by Schmieder [12], studies have reported inconsist-
ent conclusions regarding the efficacy and safety of RDN,
and there is no comprehensive review on RDN for CKD
hypertension. This systematic review and meta-analysis
aimed to evaluate the efficacy and safety of RDN in the treat-
ment of hypertension in patients with CKD.
Materials and methods
Search strategy
We performed a systematic search in PubMed, Web of
Science, Embase, and Ovid databases from their inception to
30 November 2020. The terms used were (‘renal sympathetic
denervation’ OR ‘renal nerve ablation’ OR ‘renal denervation’)
AND (‘chronic kidney disease’ OR ‘end stage renal disease’)
AND (‘blood pressure’ OR ‘hypertension’). We did not impose
any filter on text availability or the publication date. This
meta-analysis is reported in line with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses statement
and was registered in the International Prospective Register




This review focused on patients with CKD, including those
with CKD stages 1–5 and CKD5D stage, and those older than
18 years of age with hypertension.
Intervention
In this review, we included any transcatheter renal sympa-
thetic denervation procedure performed using contemporary
percutaneous catheters and radiofrequency probes.
Design
Prospective or retrospective studies were included.
Comparison
The comparison between the investigated group and the
comparator group is not yet possible since there has been
no comparator group in the vast majority of
included studies.
Outcome measures
The primary outcome measure was BP control (change in
office or clinic, 24-h mean ambulatory, ambulatory daytime
mean, and night mean systolic and diastolic BPs). Secondary
outcomes were kidney function (change in the estimated
glomerular filtration rate [eGFR] and urinary albumin-to-cre-
atinine ratio [UACR], and the need for renal replacement
therapy), heart rate, use rate of antihypertensive drugs, and
adverse effects, including but not limited to bleeding, fem-
oral artery pseudoaneurysm, renal artery dissection, transient
dizziness, and flank pain.
Eligibility criteria
The criteria for inclusion of a study in the meta-analysis were
as follows. (1) Original research papers written in English. (2)
The study participants were humans. (3) The studies were
prospective or retrospective. (4) The study compared
pre-ablative and post-ablative clinical results, including the
primary or secondary outcomes described above. (5) The
follow-up period was at least 3months after ablation.
The following publications were excluded: (1) abstracts, case
reports, case series, editorials, reviews; (2) studies based on
animal experiments; (3) studies based on pediatric popula-
tions; and (4) studies lacking relevant outcome data. The
included studies were selected independently by two investi-
gators (M.X. and T.L.). A third investigator (Y.H.) was the arbi-
trator in cases of disagreement.
Data extraction and quality assessment
Two investigators (M.X. and T.L.) independently performed
data extraction using a standard electronic data extraction
form. The abstracted data included the period, country, and
type of study and the baseline characteristics of the included
patients, such as age, sex, body mass index, follow-up time,
CKD stage, and the aforementioned main outcomes (BP,
eGFR, adverse events, and so on).
Study quality was assessed using the Newcastle-Ottawa
Scale (NOS), which is an effective tool for evaluating non-
randomized studies, including case-control and cohort
studies. This ‘star system’ was judged on three broad per-
spectives: the selection of the study groups, the comparabil-
ity of the groups, and the ascertainment of either the
exposure or outcome of interest for case-control or cohort
studies, respectively. A study with five or more stars in total
was defined as high quality.
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Data synthesis and statistical analysis
Before the analysis, data were standardized into equivalent
units, and the median and extreme values or quartile data
were converted to mean and standard deviation [13]. For
continuous variables, weighted mean differences (WMD) with
95% confidence intervals (CIs) were calculated for each study.
For categorical variables, each single proportion is expressed
as an effect size (ES) and 95% CIs [14]. Heterogeneity was
evaluated using the Cochrane Q test and I2 statistic to assess
the degree of inter-study variation. I2 values of 0–24.9%,
25–49.9%, 50–74.9%, and 75–100% were considered as hav-
ing no, mild, moderate, and significant thresholds for statis-
tical heterogeneity, respectively. A fixed-effects model was
applied when there was no or low heterogeneity (I2 <50%),
whereas a random-effects model was applied when there
was moderate or high heterogeneity (I2 >50%) [15,16].
Publication bias was assessed using the Egger’s test [17].
Sensitivity analysis was performed to identify the influence
of an individual study on pooled estimates by removing one
study at a time [15]. Data analysis was performed using
STATA 14.0 (StataCorp, College Station, TX, USA), with
p< 0.05 considered statistically significant.
Results
Included studies
We retrieved 444 articles from the databases, and 246 articles
remained after eliminating duplicate articles. After reviewing
the titles and abstracts, 214 patients were excluded after
implementing the eligibility criteria. Of the 35 studies
included in the full-text evaluation, seven were excluded
because they were case reports, three were excluded
because of the study protocol, two were excluded for insuffi-
cient data, two were excluded for duplicate patient data, and
10 did not meet the inclusion criteria. Finally, 11 single-cen-
ter, non-randomized, uncontrolled studies were included in
the meta-analysis (Figure 1) [18–28]. These 11 studies
included 238 patients and are summarized in Table 1. The
NOS assessments are presented in Table 2. All studies had
NOS scores of more than five stars, which were considered
to indicate high quality.
Blood pressure
As shown in Table 3 and Figures 2 and 3, the results of the
summary analysis of office BP and 24-h ambulatory BP moni-
toring (24 h ABPM), including office systolic BP (SBP) and
office diastolic BP (DBP), showed a decreasing trend between
before and after RDN. Among them, two articles [21,28]
reported 24 h ABP 1month after RDN. There was a significant
difference in office SBP and office DBP between before and
1month after RDN (all, p< 0.001), with no heterogeneity
(Table 3). This significant difference in office SBP continued
at 3, 6, and 12months. By 24months, there were still two
articles [21,24] that recorded 24 h ABP, and there was a sig-
nificant difference in 24 h ABP between before and
24months after RDN (SBP: p< 0.001, DBP: p¼ 0.001), with
mild and no evidence of heterogeneity, respectively
(Table 3).
Only two trials [26,28] in which the 24-h ambulatory SBP
and DBP could be calculated from the data reported were
included in the subgroup analysis of patients with end-stage
renal disease (ESRD). The results showed that the treatment
may lower 24-h ambulatory SBP and DBP between before
and 6months after RDN for hypertension in patients with
ESRD (all p< 0.001), with no significant heterogeneity
(Figure 4).
Figure 1. Flow diagram outlining article selection process.
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Renal function
As shown in Table 4, two articles reported eGFR values at
1month [21,23], four articles reported eGFR values at
3months and 6months [18,21,23,27], three articles reported
eGFR values at 12months [20,21,27], and two articles
reported eGFR values at 24months after RDN [21,27]. The
heterogeneity among the studies was significant; therefore,
the random-effects model was used for the analysis (Table
4). The eGFR measurements obtained at 1month, 3months,
6months, 12, and 24months after RDN were not significantly
different from those obtained before RDN (all, p> 0.05), as
shown in Figure 5 and Table 4.
Data on UACR levels were reported in four studies
[18,21,23,27] (Table 4). UACR levels were significantly reduced
at 3months and 6months after RDN (all, p< 0.001). There
was no heterogeneity among the studies; therefore, the
fixed-effects model was used for the analysis (Figure 6 and
Table 4). However, UACR levels at 12 and 24months after
RDN were not significantly different from those obtained
before RDN (all p> 0.05) (Table 4). The heterogeneity among
the studies was moderate at 12months and significant at
24months after RDN; therefore, the random-effects model
was used for the analysis (Figure 6 and Table 4).
Heart rate
Two articles [18,24] reported changes in the heart rate at
3months, and three trials [18,24,26] reported data at
6months after RDN. No difference was found before and
after the procedure (all, p> 0.05), with no heterogeneity
among the studies (Figure S1).
Antihypertensive drugs
Overall, four trials [19,21,27,28] reported data on antihyper-
tensive medications before and after RDN. The results of the
summary analysis showed a significant decrease in antihyper-
tensive medications after RDN (p< 0.001), with moderate
heterogeneity among the studies (Figure S2).
Adverse events
Three major complications (hematoma, femoral pseudoa-
neurysm, and bleeding) were reported after RDN
[19,21,23,25]. Only one article reported the data of the bleed-
ing complication [21]. The incidence of pseudoaneurysm was
1.3% (3/238, p¼ 0.07), with no heterogeneity among the
studies, and the incidence of hematoma was 2.9% (7/238,
p¼ 0.206), with significant heterogeneity among the studies
(Figure S3).
Two cases of progression to ESRD and one case of dialy-
sis-related complications were recorded in two trials [23,25];
however, these events occurred several months after the
procedure, and their occurrence was related to the patients’
kidney disease. One patient had a myocardial infarction that
was not ruled out to be related to his own disease [25].
Therefore, they were not considered as procedure-
related events.
Sensitivity analyses and publication bias
Sensitivity analyses for changes in the BP, eGFR, and UACR
level at each month after RDN were used to judge the
dependability of the results. One study was deleted at a
time, and no such deletion had any significant impact on the
results, as shown in Figure 7.
Publication bias analyses were conducted for primary out-
comes. No evidence of publication bias was detected for the
BP using the Egger test (Table 5).
Discussion
To our knowledge, the present study is the first meta-ana-
lysis to evaluate the efficacy and safety of RDN for hyperten-
sion in patients with CKD. The overall outcome showed that
individuals treated with RDN experienced significantly
greater 24-h BP and diastolic BP reductions, and RDN did not




















Hering 2012 Germany/Australia NR 15 61 ± 9 33 ± 8 9/ 6 73 CKD3–4 31.2 ± 8.9 12
Ott 2015 Germany NR 27 63.4 ± 9.4 31.2 ± 4.8 22/5 56 CKD3–4 48.5 ± 12 12
Schlaich 2013 Germany NR 9 47.4 ± 13.0 24.1 ± 2.7 NR NR CKD5D <15 24
Kiuchi 2016 Brazil/USA 2011–2012 30 55 ± 10 NR 23/17 37 CKD2–4 61.9 ± 23.9 24
Kiuchi 2016’ Brazil 2012–2016 48 57.5 ± 10.2 26.8 ± 5.4 NR 22 CKD2–4 55.7 ± 33.0 6
Hering 2017 Australia NR 46 66 ± 9 NR 28/18 48 CKD3–4 46.2 ± 13.0 24
Hoye 2017 New Zealand 2012–2013 9 59 ± 9 25 ± 2 8/1 22.2 CKD5D <15 12
Hameed 2017 UK NR 11 57.3 ± 4.9 32.5 ± 3.8 8/3 45.5 CKD3–4 29.3 ± 6.6 6
Ott 2019 Germany NR 6 42.5 ± 15.2 22.7 ± 3.1 4/2 16.7 CKD5D <15 6
Prasad 2019 Canada 2013–2014 25 62.8 ± 12.4 33.5 ± 6 NR NR CKD3–4 37.5 ± 4.8 24
Scalise 2020 Italy 2017–2018 12 56.5 ± 16.5 NR 8/4 33.3 CKD5D <15 12
Abbreviations: BMI: Body Mass Index; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; NR: not available; M: male; F: female; m: month.
Table 2. Quality Assessment of the Included Studies
Study Selection Comparability Outcome Scores
Hering 2012 qqq qq qq 7
Ott 2015 qqq qq qq 7
Schlaich 2013 qqq qq qq 7
Kiuchi 2016 qqq qq qqq 8
Kiuchi 2016’ qqq qq qqq 8
Hering 2017 qqq qq qq 7
Hoye 2017 qqq qq qq 7
Hameed 2017 qqq qq qq 7
Ott 2019 qqq qq qqq 8
Prasad 2019 qqq qq qq 7
Scalise 2020 qqq qq qqq 8
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increase the risk of rapid deterioration of renal function and
other major adverse events.
In our study, a significant decrease in the average 24-h
and office BP was observed 1month after RDN. Similar to
previous studies on the renal sympathetic nerve in patients
with resistant hypertension, our review of ABPM and office
BP obtained during a follow-up period of 24months showed
a significant decrease in the ambulatory BP, especially the
systolic ambulatory BP after RDN. This difference was main-
tained until 1, 3, 6, 12, and 24months postoperatively
[29,30]. As a more selective method of reducing renal sympa-
thetic secretion, RDN effectively removes sympathetic nerve
overactivity and leads to a systemic decrease in sympathetic
tone [31]. In particular, sympathetic nerve activity is more
obvious in CKD, and the degree of sympathetic nerve over-
drive increases with disease progression [32]. Previous
research also suggests that the role of sympathetic overactiv-
ity in driving sustained hypertension is derived from its
effects on renal function; RDN interrupts renal afferent and
efferent sympathetic nerves, which modulate central sympa-
thetic outflow and renal physiology to achieve sustained BP
reduction in patients with CKD [33,34]. RDN can also reduce
increased renin secretion and increased renal tubular sodium
reabsorption caused by renal sympathetic nerve activity,
thereby inhibiting the renin-angiotensin system and achiev-
ing the purpose of lowering BP [35,36]. Furthermore, RDN
may affect peripheral vascular resistance by significantly
reducing the sympathetic trophic effect on arteriolar walls
and arterial stiffness in patients with CKD, which is more
conducive to lowering BP [18,37]. However, it is unknown
how long BP reduction is maintained as sympathetic nerves
recover after the lesion [38]. Data showed that DBP and SBP
levels were significantly lower at 24months after RDN, and
neither the recovery of nerve fibers nor the effective coun-
ter-regulatory mechanism that elevates BP was found [39].
Even 36months after RDN, BP was significantly lower than
before RDN [40].
Subgroup analysis of ESRD patients with hypertension
showed similar changes in the BP after RDN treatment. This
finding is in line with those of previous reports in patients
with ESRD, and shows that BP reduction accompanying renal
denervation was greater than that during the whole CKD
Table 3. Pooled effect on different type blood pressure at different timepoint.
Measure No. of studies
Heterogeneity Estimate
I2 (%) p Valuea Pooled WMD [95% CI] p Valueb
1-Month
Office SBP 3 95.2 <0.001 25.719 [47.175, 4.264] 0.019
Office DBP 3 85.2 0.001 10.561 [19.612, 1.511] 0.022
24h ABPM SBP 2 0 0.912 17.186 [24.094, 10.278] <0.001
24 h ABPM DBP 2 0 0.746 9.353 [13.968, 4.738] <0.001
3-Month
Office SBP 5 95.8 <0.001 22.678 [37.538, 7.819] 0.003
Office DBP 4 91.6 <0.001 9.734 [20.071, 0.602] 0.065
24h ABPM SBP 3 71.8 0.029 9.465 [18.712, 0.218] 0.045
24h ABPM DBP 3 15.5 0.306 4.715 [7.888, 1.543] 0.004
Ambulatory daytime SBP 3 96.9 <0.001 13.687 [36.951, 9.577] 0.249
Ambulatory daytime DBP 3 70.3 0.034 0.712 [4.934, 6.358] 0.805
Ambulatory nighttime SBP 3 38.5 0.197 3.412 [6.688, 0.136] 0.041
Ambulatory nighttime DBP 3 65.6 0.055 1.774 [6.313, 2.764] 0.444
6-Month
Office SBP 6 94.1 <0.001 23.746 [35.464, 12.029] <0.001
Office DBP 5 90.9 <0.001 10.314 [18.419, 2.209] 0.013
24h ABPM SBP 6 90.8 <0.001 11.716 [23.270, 0.163] 0.047
24h ABPM DBP 6 79.3 <0.001 6.103 [12.273, 0.067] 0.053
Ambulatory daytime SBP 6 81.1 <0.001 4.658 [10.475, 1.158] 0.116
Ambulatory daytime DBP 6 78.6 <0.001 3.908 [9.617, 1.801] 0.180
Ambulatory nighttime SBP 6 89.0 <0.001 8.970 [18.797, 0.856] 0.074
Ambulatory nighttime DBP 6 80.7 <0.001 4.046 [9.265, 1.173] 0.129
12-Month
Office SBP 5 95,6 <0.001 28.479 [45.519, 11.440,] 0.001
Office DBP 4 88.8 <0.001 13.111 [21.353, 4.870] 0.002
24h ABPM SBP 4 80.4 0.002 14.325 [24.153, 4.497] 0.004
24h ABPM DBP 4 60.3 0.056 6.915 [11.849, 1.981] 0.006
Ambulatory daytime SBP 3 62.3 0.070 4.747 [11.732, 2.237] 0.183
Ambulatory daytime DBP 3 76.6 0.014 5.725 [12.757, 1.306] 0.110
Ambulatory nighttime SBP 3 87.4 <0.001 11.031 [24.092, 2.031] 0.098
Ambulatory nighttime DBP 3 78.2 0.010 3.589 [10.135, 2.958] 0.283
24-Month
Office SBP 2 98.5 <0.001 35.285 [71.542, 0.972] 0.056
Office DBP 2 96.0 <0.001 10.895 [28.534, 6.743] 0.226
24h ABPM SBP 2 38.0 0.204 17.102 [23.591, 10.613] <0.001
24 h ABPM DBP 2 0 0.329 6.896 [10.907, 2.885] 0.001
Ambulatory daytime SBP 2 81.6 0.020 4.009 [17.591, 9.572] 0.563
Ambulatory daytime DBP 2 90.4 0.001 2.707 [12.490, 7.076] 0.588
Ambulatory nighttime SBP 2 81.9 0.019 3.472 [13.930, 20.874] 0.696
Ambulatory nighttime DBP 2 0 0.356 1.674 [0.649, 3.996] 0.158
SBP: systolic blood pressure; DBP: diastolic blood pressure; 24 h ABPM: 24 h mean ambulatory blood pressure monitoring.
aHeterogeneity was defined as I2 >50% or p< 0.10; bSignificance was set at p< 0.05.
Bold values indicate statistically significant results.
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Figure 2. Forest plots of comparison between (A) office systolic-BP at six months after RDN and that of pre-ablation. (B) Office diastolic-BP at six months after RDN
and that of pre-ablation. (C) Office systolic-BP at 12months after RDN and that of pre-ablation. (D) Office diastolic-BP at 12months after RDN and that of
pre-ablation.
Figure 3. Forest plots of comparison between (A) 24-h ambulatory systolic-BP at six months after RDN and that of pre-ablation. (B) 24-h ambulatory diastolic-BP at
six months after RDN and that of pre-ablation. (C) 24-h Ambulatory systolic-BP at 12months after RDN and that of pre-ablation. (D) 24-h Ambulatory diastolic-BP
at 12months after RDN and that of pre-ablation.
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stage. This may originate from the fact that patients with
advanced CKD and ESRD are more likely to have increased
sympathetic nerve activity given their impaired capacity for
sodium and fluid excretion and increased sympathetic drive
[41,42]. Furthermore, in patients with ESRD, the increase in
nerve density in the internal area of the periadventitial tissue
may have also played a role [42]. This implies that RDN may
target more nerves in patients with ESRD than in other
hypertensive patients [43]. It is also possible that the increas-
ing improvement and completion of RDN catheters and a
higher number of renal artery ablations can be performed
[28], thereby more effectively destroying sympathetic fibers
within the renal tissue. However, compared to patients with
CKD who are not undergoing long-term dialysis, the BP of
patients with ESRD is affected by many factors, such as the
volume load, electrolytes, and other interference factors [44].
Therefore, further well-designed large clinical trials are
needed to determine the potential role of this in ESRD, given
that activation of sympathetic nerve activity has been
described as a crucial component in the development and
progression of CKD [45].
There is growing evidence that therapeutic sympathetic
nerve ablation aimed at targeting renal nerves may have
potential benefits for CKD [20,24]. The BP-lowering effect of
RDN can have a protective effect on the kidney, as the
detrimental effect of hypertension on renal function has
been well established [46]. Inhibition of renal sympathetic
nerve activity may lead to prominent vasodilatation in pre-
glomerular arterioles, decreased renal vascular resistance,
and increased renal blood flow, which may be the major
determinants of improved renal function [47]. Our data
showed that the eGFR was unchanged and urinary albumin
excretion, usually expressed as total UACR [48], was signifi-
cantly reduced at 1, 3, and 6months after catheter-based
RDN, suggesting that RDN and the associated hemodynamic
changes have no adverse effects on the kidneys. Although it
is unclear whether the unchanged eGFR was related to the
progression of individual differences in CKD progression,
urinary albumin excretion, as an early marker of CKD pro-
gression [49], is encouraging in the early postoperative fol-
low-up.
Regarding complications and adverse effects after RDN,
among the 238 patients in the 11 studies included, there
was one case of bleeding, three cases of pseudoaneurysm,
and seven cases of hematoma among the adverse reactions
related to puncture-site complications, which are common
with any percutaneous angiographic procedure [23]. The
heart rate showed no significant changes after treatment.
Moreover, no incidence of electrolyte disturbances, including
hyperkalemia, hypokalemia, hypercalcemia, and
Figure 4. Forest plots of subgroup analysis in ESRD (A) 24-h ambulatory systolic-BP at six months after RDN and that of pre-ablation. (B) 24-h Ambulatory dia-
stolic-BP at six months after RDN and that of pre-ablation.
Table 4. Pooled effect on renal function at different timepoint.
Measure NO. of studies
Heterogeneity Estimate
I2 (%) p Valuea Pooled WMD [95% CI] p Valueb
1-Month
eGFR (mL/min/1.73 m2) 2 71.1 0.063 5.301 [8.536, 19.138] 0.453
3-Month
eGFR (mL/min/1.73 m2) 4 38.0 0.184 0.057 [2.456, 2.571] 0.964
UACR (mg/g) 4 0 0.852 51.731 [71.197, 32.265] <0.001
6-Month
eGFR (mL/min/1.73 m2) 4 69.7 0.019 0.801 [4.795, 6.397] 0.779
UACR (mg/g) 4 0 0.796 75.538 [90.960, 60.115] <0.001
12-Month
eGFR (mL/min/1.73 m2) 3 77.6 0.011 5.711 [3.792, 15.215] 0.239
UACR (mg/g) 2 51.1 0.153 51.328 [152.367, 49.711] 0.319
24-Month
eGFR (mL/min/1.73 m2) 2 90.2 0.001 10.830 [16.711, 38.370] 0.441
UACR (mg/g) 2 92.8 < 0.001 103.337[301.147, 507.821] 0.617
eGFR: estimated glomerular filtration rate; UACR: urinary albumin-to-creatinine ratio.
aHeterogeneity was defined as I2 >50% or p< 0.10; bsignificance was set at p< 0.05.
Bold values indicate statistically significant results.
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Figure 5. Forest plots of comparison between (A) eGFR at three months after RDN and that of pre-ablation. (B) eGFR at six months after RDN and that of pre-abla-
tion. (C) eGFR at 12months after RDN and that of pre-ablation. (D) eGFR at 24months after RDN and that of pre-ablation.
Figure 6. Forest plots of comparison between (A) UACR at three months after RDN and that of pre-ablation. (B) UACR at six months after RDN and that of pre-abla-
tion. (C) UACR at 12months after RDN and that of pre-ablation. (D) UACR at 24months after RDN and that of pre-ablation.
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hypocalcemia, was reported in our included studies after the
procedure, supporting that renal denervation may not
adversely affect autoregulation of the kidneys [50]. No ser-
ious procedure-related complications (including all-cause
death, major cardiovascular events, perioperative complica-
tions, and hypertension crisis) were reported.
There are several limitations to our analysis. First, signifi-
cant heterogeneity was found in some pooled results, which
may be due to the (1) source and number of populations, (2)
different CKD stages, (3) varied ablation types, and (4) the
heterogeneity of some measurement methods, such as the
office BP measurement. We attempted to explore this rela-
tionship between studies by pooling the data using sensitive
analysis and subgroup analysis. However, some heterogene-
ities could not be avoided because of the limited number of
included studies. Second, the number of included studies
and sample size were small; although this might not have
caused obvious publication bias, there is still potential for
bias. Third, most of the studies will focus on the efficacy of
treatment more than 24months after surgery in the future,
so there is not enough current information to analyze the
long-term efficacy of RDN. Finally, after searching the data-
base thoroughly, no relevant randomized controlled trials
were found. Thus, well-designed randomized controlled trials
of RDN are urgently needed to confirm the safety and
Figure 7. Results of sensitivity analyses. (A) Office systolic-BP at six months after RDN and that of pre-ablation. (B) Office Diastolic-BP at six months after RDN and
that of pre-ablation. (C) 24-h ambulatory Systolic-BP at six months after RDN and that of pre-ablation. (D) 24-h ambulatory Diastolic-BP at six months after RDN
and that of pre-ablation.
Table 5. Assessment of publication bias based on different outcome.
Primary outcomes Follow-up time point t p Valuea








24h ABPM SBP 3months 2.66 0.968
6months 2.35 0.073
12months 1.85 0.255
24h ABPM DBP 3months 0.84 0.367
6months 1.63 0.088
12months 1.04 0.154
Ambulatory daytime SBP 3months 3.09 0.252
6months 2.02 0.191
12months 1.15 0.332
Ambulatory daytime DBP 3months 1.10 0.278
6months 1.71 0.117
12months 0.70 0.154
Ambulatory nighttime SBP 3months 1.01 0.756
6months 0.69 0.390
12months 0.93 0.655
Ambulatory nighttime DBP 3months 0.87 0.235
6months 1.62 0.073
12months 0.37 0.077
SBP: systolic blood pressure; DBP: diastolic blood pressure; 24 h ABPM: 24 h
mean ambulatory blood pressure monitoring.
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reproducibility of this treatment and to assess its impact on
clinical outcomes in the future.
Conclusions
In conclusion, our meta-analysis indicates that RDN may be
effective and safe for treating CKD patients with hyperten-
sion. It helped achieve a highly significant reduction in BP
with no adverse reaction to renal function and enabled a
substantial reduction in the number of antihypertensive
drugs used. Moreover, RDN was associated with reduced
albumin excretion during this short follow-up period, and no
major complications occurred.
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